Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Alterity Therapeutics ( (AU:ATH) ) is now available.
Alterity Therapeutics has notified the market of the planned issue of 61,500,000 unlisted options under its employee incentive scheme. The options, which carry an exercise price of US$0.0057 and expire on March 26, 2031, are not intended to be quoted on the ASX.
The issuance of these unquoted options underscores Alterity’s continued reliance on equity incentives to align employee interests with long-term shareholder value. This move may help the company retain and motivate staff while potentially diluting existing holders if the options are exercised over time.
The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a biotechnology company listed on the ASX under the code ATH. The company operates in the life sciences sector, focusing on developing therapeutic products, and uses equity-based incentive schemes to compensate and retain employees and key personnel.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$87M
See more data about ATH stock on TipRanks’ Stock Analysis page.